Novel FGFR2b-targeting ADC is approved by the U.S. FDA to enter clinical trials
NDA of Rademikibart, Jointly Developed by Simcere and Connect Biopharma for the Treatment of Atopic Dermatitis Accepted by NMPA
QUVIVIQ® - The World’s New Generation Anti-Insomnia Drug – Approved for Launch,Significantly Improves Sleep and Daytime Functioning
Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma
Simcere Zaiming and NextCure Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
2025 ASCO | Simcere Zaiming Showcases the Latest Clinical Data in 18 Studies for 5 Innovative Products
Simcere Zaiming Announces Phase 3 Clinical Trial Results for Cetuximab β Injection (Enlituo)
Simcere Zaiming will present 7 innovative researches at the 2025 AACR
Simcere Zaiming’s FGFR2b targeting ADC SIM0686 obtained IND approval from China NMPA
NDA of Deunoxavir Marboxil ,the Next Generation Innovative Influenza Drug get Accepted , Offering Hope for "One-Pill Cure" for Influenza.